Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) Gross Margin (2016 - 2025)

Historic Gross Margin for Fortress Biotech (FBIO) over the last 11 years, with Q3 2025 value amounting to 67.36%.

  • Fortress Biotech's Gross Margin fell 20800.0% to 67.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 67.64%, marking a year-over-year decrease of 28500.0%. This contributed to the annual value of 63.8% for FY2024, which is 91100.0% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Gross Margin is 67.36%, which was down 20800.0% from 69.91% recorded in Q2 2025.
  • Fortress Biotech's 5-year Gross Margin high stood at 88.73% for Q4 2023, and its period low was 47.04% during Q3 2021.
  • Moreover, its 5-year median value for Gross Margin was 61.55% (2024), whereas its average is 62.15%.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -209800bps in 2021, then surged by 357800bps in 2023.
  • Fortress Biotech's Gross Margin (Quarter) stood at 47.88% in 2021, then rose by 11bps to 52.95% in 2022, then skyrocketed by 68bps to 88.73% in 2023, then dropped by -22bps to 69.05% in 2024, then dropped by -2bps to 67.36% in 2025.
  • Its Gross Margin was 67.36% in Q3 2025, compared to 69.91% in Q2 2025 and 63.54% in Q1 2025.